NCT00320463View on ClinicalTrials.gov

Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants

PHASE3CompletedINTERVENTIONAL

Enrollment

415

Participants

Timeline

Start Date

April 30, 2006

Study Completion Date

January 31, 2007

Conditions

DiphtheriaHepatitis BPoliomyelitisTetanusAcellular Pertussis

Interventions

BIOLOGICAL

DTPa-HBV-IPV/Hib vaccine

Trial Locations (4)

167002

GSK Investigational Site, Syktyvkar

167011

GSK Investigational Site, Syktyvkar

183046

GSK Investigational Site, Murmansk

614022

GSK Investigational Site, Perm

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY